Fourteen PMR-patients and 21 SMR-patients who met the study criteria were evaluated for the study. No difference was detected in terms of age, BMI, pregnancy, vaginal delivery, menopause status, DM, smoking status, genitourinary system symptoms, PVR, previous midurethral surgery, and mesh removal time from implantation, between two groups (p=0.583, p=0.561, p=0.359, p=0.606, p=0.594, p=0.530, p=0.533, p=0.218, p=0.630, p=0.647, p=0.359, respectively). In PMR-patients, the length of the removed mesh (2.71±0.62 cm vs 7.33±0.85 cm, p=0.001), and the duration of operation (57.28±4.77 minute vs 69.52±6.4, p=0.001) were shorter. No patients had per-operative or post-operative complications (Table 1).
At the post-operative 6th month, there was a significant improvement in UDI-6 scores and FSFI scores in both PMR, and SMR groups (p=0.001, p=0.001, p=0.001, p=0.001, respectively). When the two groups were compared in terms of improvement rates, there was no significant difference in UDI-6 scores [(-) 30.21 ± 6.56%, vs (-) 26.33 ± 9.01%, p=0.222 ]. However, there was a statistically significant improvement in the FSFI scores in the SMR group [(+) 83.71 ± 14.81%, vs (+) 124.42 ± 36.82%, p=001]. Following mesh excision, there was no significant difference in overactive bladder (OAB) symptoms between 2 groups, with a decrease of 75% in the PMR group and 71.42% in the SMR group (p=0.721). Recurrent SUI was observed in 2 (14.2%) patients in the PMR group, and 4 (19.1%) in the SMR group at the post-operative 6th month, but no significant difference was found between two groups (p=0.544) (Table 2).